We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Neuropathic Post-Zosterian Pain on the Cognition

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00989040
First Posted: October 2, 2009
Last Update Posted: January 30, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University Hospital, Clermont-Ferrand
  Purpose
Pain is defined as a sensorial and emotional phenomenon and lead consequences on the cognition. These consequences could be increased with usual treatment. So the aim of this study is to explore these cognitive consequences.

Condition Intervention Phase
Neuropathic Post-zosterian Pain Cognition Drug: usual treatment: Versatis Phase 1

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Impact of Neuropathic Post-zosterian Pain on the Cognition (NPZ and Cognition)

Further study details as provided by University Hospital, Clermont-Ferrand:

Primary Outcome Measures:
  • The principal outcome is to explore if the cognition is failed in treated patients suffering of neuropathic post-zosteria pain. [ Time Frame: at day 1 ]

Secondary Outcome Measures:
  • Study if treated patients with patch (Versatis®) have better cognition than treated patients without patch. [ Time Frame: at day 1 ]

Enrollment: 100
Study Start Date: March 2009
Study Completion Date: September 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: usual treatment: Versatis
    • To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.
    • To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch.
Detailed Description:
Pilot prospective study with parallel groups
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients who suffer of neuropathic post-zosteria pain
Criteria

Inclusion Criteria:

  • Patient suffering of NPZ pain
  • Over 55 years old
  • Healthy volunteers
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00989040


Locations
France
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Investigators
Principal Investigator: Claude Dubray, PUPH CIC-CPC Clermont-Ferrand
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT00989040     History of Changes
Other Study ID Numbers: CHU-0049
First Submitted: March 13, 2009
First Posted: October 2, 2009
Last Update Posted: January 30, 2012
Last Verified: January 2012

Keywords provided by University Hospital, Clermont-Ferrand:
NPZ
Pain


To Top